Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Mallinckrodt
US Department of Justice
Julphar
Cerilliant
Fish and Richardson
Dow
McKesson
McKinsey

Generated: December 10, 2017

DrugPatentWatch Database Preview

ALTOPREV Drug Profile

« Back to Dashboard

Which patents cover Altoprev, and when can generic versions of Altoprev launch?

Altoprev is a drug marketed by Covis Pharma Bv and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-three patent family members in twelve countries.

The generic ingredient in ALTOPREV is lovastatin. There are thirty-three drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the lovastatin profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-001Jun 26, 2002DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-003Jun 26, 2002RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-002Jun 26, 2002RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-004Jun 26, 2002RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-003Jun 26, 2002RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-001Jun 26, 2002DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-001Jun 26, 2002DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-002Jun 26, 2002RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-002Jun 26, 2002RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-004Jun 26, 2002RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ALTOPREV

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,679,534HMG-CoA reductase inhibitor extended release formulation► Subscribe
6,440,387 Methods for determining risk of Alzheimer's disease► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ALTOPREV

Country Document Number Estimated Expiration
European Patent Office1035842► Subscribe
Germany10085183► Subscribe
Japan4646400► Subscribe
Australia1627599► Subscribe
Japan2002507564► Subscribe
Japan5132721► Subscribe
Germany69832092► Subscribe
Germany20023538► Subscribe
Hong Kong1050134► Subscribe
United Kingdom2371748► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Chubb
Novartis
Boehringer Ingelheim
Accenture
Colorcon
Fuji
Healthtrust
Covington
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot